Lynne Sullivan's most recent trade in Solid Biosciences Inc was a trade of 77,500 Director Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Solid Biosciences Inc | Lynne Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 77,500 | 77,500 | - | - | Director Stock Option (Right to Buy) | |
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 02 Apr 2025 | 21,867 | 98,905 (0%) | 0% | 1.0 | 22,523 | Common Stock, $0.0001 par value | |
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 28 Mar 2025 | 106,000 | 106,000 | - | - | Stock Option (Right to Buy) | ||
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 28 Mar 2025 | 65,000 | 120,772 (0%) | 0% | 0 | Common Stock, $0.0001 par value | ||
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 04 Feb 2025 | 153 | 55,772 (0%) | 0% | 2.2 | 341 | Common Stock, $0.0001 par value | |
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 22 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | ||
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 04 Nov 2024 | 136 | 55,925 (0%) | 0% | 1.3 | 175 | Common Stock, $0.0001 par value | |
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 02 Aug 2024 | 139 | 56,061 (0%) | 0% | 1.5 | 213 | Common Stock, $0.0001 par value | |
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 25 Jun 2024 | 324 | 32,685 (0%) | 0% | 1.4 | 454 | Common Stock, $0.0001 par value | |
| Inozyme Pharma Inc | Lynne Sullivan | Director | 18 Jun 2024 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | ||
| Solid Biosciences Inc | Lynne Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 34,400 | 34,400 | - | - | Director Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Lynne Sullivan | Director | 13 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | ||
| Solid Biosciences Inc | Lynne Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,650 | 9,650 | - | - | Director Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Lynne Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 9,650 | 9,650 | - | - | Director Stock Option (Right to Buy) | |
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 18 Nov 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | ||
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 18 Nov 2022 | 925 | 33,009 (0%) | 0% | 6.9 | 6,373 | Common Stock, $0.0001 par value | |
| Inozyme Pharma Inc | Lynne Sullivan | Director | 10 Jun 2022 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | ||
| Solid Biosciences Inc | Lynne Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 51,000 | 51,000 | - | - | Director Stock Option (Right to Buy) | |
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 09 Feb 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | ||
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 09 Feb 2022 | 50,000 | 326,785 (0%) | 0% | 0 | Common Stock, $0.0001 par value | ||
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 24 Jun 2021 | 123,333 | 123,333 | - | - | Stock Option (Right to Buy) | ||
| Unity Biotechnology Inc | Lynne Sullivan | CFO & Head of Corp. Dev. | 24 Jun 2021 | 30,833 | 270,833 (0%) | 0% | 0 | Common Stock, $0.0001 par value | ||
| Inozyme Pharma Inc | Lynne Sullivan | Director | 23 Jun 2021 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | ||
| Unity Biotechnology Inc | Lynne Sullivan | Chief Financial Officer | 13 Sep 2020 | 240,000 | 240,000 (0%) | 0% | 0 | Common Stock, $0.0001 par value | ||
| Unity Biotechnology Inc | Lynne Sullivan | See Remarks | 01 Aug 2020 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | ||
| Inozyme Pharma Inc | Lynne Sullivan | None | 23 Jul 2020 | 9,367 | 9,367 | - | - | Stock Option (right to buy) |